04.12.23
Open Book Extracts (OBX), an ingredient manufacturer and product developer of cannabinoid-containing products, has appointed Andrea Baillo as chief scientific officer. Baillo previously held the position of vice president of research and product innovation.
In her new role, Baillo will oversee all research and development efforts at OBX, including ingredient R&D, product development, and ingredient and product safety and efficacy research. She will lead global research engagements with partners, clients, academia, and non-governmental organizations and help build the pipeline of science and technology talent at OBX. She will lead the company’s research and product development teams.
Baillo is an experienced scientist with a history of working in cannabis research, development, and manufacturing, as well as cancer research, and research in the food and beverage industries. She has historically focused on product safety and stability, as well as research which was at the forefront of R&D in highly-regulated markets.
“OBX is committed to leveraging data to deliver better products and outcomes to consumers. With more than 15 years of research experience, Andrea brings the expertise needed to advance our business and scientific understanding of the endocannabinoid system and the products that best support it,” said Dave Neundorfer, OBX chief executive officer. “We look forward to her leadership of OBX’s ambitious scientific goals.”
“I am eager to be driving discoveries that have the potential to impact not only the future of our business, but also to improve the quality of life for people globally,” said Baillo. “I’m fortunate to be surrounded by some of the best and brightest scientists, researchers and professionals at OBX, and looking forward to continuing our important work together.”
“Andrea Baillo is undeniably a trailblazer in the field of cannabinoid science, and she is eager for other women to join her,” said Neundorfer. “Women are seriously under-represented in science across the world. Within OBX, we support women to unlock their potential as well as inspiring the next generation of women to pursue careers in STEM.”
OBX has partnered with contract research organization Radicle Science on three controlled clinical studies on minor cannabinoids on quality of life outcomes including pain, sleep, and focus. The company has also conducted safety and toxicology studies on CBN, CBC, THCV, CBDV, as well as a clinical study on the role of THCV to address acne.
In her new role, Baillo will oversee all research and development efforts at OBX, including ingredient R&D, product development, and ingredient and product safety and efficacy research. She will lead global research engagements with partners, clients, academia, and non-governmental organizations and help build the pipeline of science and technology talent at OBX. She will lead the company’s research and product development teams.
Baillo is an experienced scientist with a history of working in cannabis research, development, and manufacturing, as well as cancer research, and research in the food and beverage industries. She has historically focused on product safety and stability, as well as research which was at the forefront of R&D in highly-regulated markets.
“OBX is committed to leveraging data to deliver better products and outcomes to consumers. With more than 15 years of research experience, Andrea brings the expertise needed to advance our business and scientific understanding of the endocannabinoid system and the products that best support it,” said Dave Neundorfer, OBX chief executive officer. “We look forward to her leadership of OBX’s ambitious scientific goals.”
“I am eager to be driving discoveries that have the potential to impact not only the future of our business, but also to improve the quality of life for people globally,” said Baillo. “I’m fortunate to be surrounded by some of the best and brightest scientists, researchers and professionals at OBX, and looking forward to continuing our important work together.”
“Andrea Baillo is undeniably a trailblazer in the field of cannabinoid science, and she is eager for other women to join her,” said Neundorfer. “Women are seriously under-represented in science across the world. Within OBX, we support women to unlock their potential as well as inspiring the next generation of women to pursue careers in STEM.”
OBX has partnered with contract research organization Radicle Science on three controlled clinical studies on minor cannabinoids on quality of life outcomes including pain, sleep, and focus. The company has also conducted safety and toxicology studies on CBN, CBC, THCV, CBDV, as well as a clinical study on the role of THCV to address acne.
